Systemic treatment of penile squamous cell carcinoma—hurdles and hopes of preclinical models and clinical regimens: a narrative review

Página do item simplificado
dc.contributor.authorThomas, Anita
dc.contributor.authordo Canto Alvim, Luisa Matos
dc.contributor.authorRainho, Claudia Aparecida [UNESP]
dc.contributor.authorJuengel, Eva
dc.contributor.authorBlaheta, Roman Alexander
dc.contributor.authorSpiess, Philippe E.
dc.contributor.authorRogatto, Silvia Regina
dc.contributor.authorTsaur, Igor
dc.contributor.institutionUniversity Medicine Mainz
dc.contributor.institutionUniversity of Southern Denmark
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)
dc.contributor.institutionGoethe University Hospital Frankfurt
dc.contributor.institutionMoffitt Cancer Center
dc.date.accessioned2022-05-01T10:18:55Z
dc.date.available2022-05-01T10:18:55Z
dc.date.issued2021-10-01
dc.description.abstractDespite contemporary research efforts, the prognosis of penile squamous cell carcinoma (PeSCC) has not significantly improved over the past decade. Despite frequently encountered patient-related delayed medical consultations impairing outcomes, several other aspects contribute to the lack of advancement in the treatment of this condition. One essential reason is that translational research, a prerequisite for the clinically successful disease management, is still at an early stage in PeSCC as compared to many other malignancies. Preclinical experimental models are indispensable for the evaluation of tumor biology and identification of genomic alterations. However, since neither commercial PeSCC cell lines are available nor xenograft models sustainably established, such analyses are challenging in this field of research. In addition, systemic therapies are less effective and toxic without decisive breakthroughs over recent years. Current systemic management of PeSCC is based on protocols that have been investigated in small series of only up to 30 patients. Thus, there is an unmet medical need for new approaches necessitating research efforts to develop more efficacious systemic strategies. This review aims to highlight the current state of knowledge in the molecular alterations involved in the etiology and ensuing steps for cancer progression, existing preclinical models of translational research, clinically relevant systemic protocols, and ongoing clinical trials.en
dc.description.affiliationDepartment of Urology and Pediatric Urology University Medicine Mainz
dc.description.affiliationDepartment of Clinical Genetics University Hospital of Southern Denmark Vejle Institute of Regional Health Research University of Southern Denmark
dc.description.affiliationDepartment of Chemical and Biological Sciences Institute of Biosciences São Paulo State University (UNESP), Botucatu
dc.description.affiliationDepartment of Urology Goethe University Hospital Frankfurt
dc.description.affiliationDepartment of Genitourinary Oncology Moffitt Cancer Center
dc.description.affiliationUnespDepartment of Chemical and Biological Sciences Institute of Biosciences São Paulo State University (UNESP), Botucatu
dc.format.extent4085-4098
dc.identifierhttp://dx.doi.org/10.21037/tau-20-945
dc.identifier.citationTranslational Andrology and Urology, v. 10, n. 10 October, p. 4085-4098, 2021.
dc.identifier.doi10.21037/tau-20-945
dc.identifier.issn2223-4691
dc.identifier.issn2223-4683
dc.identifier.scopus2-s2.0-85118483493
dc.identifier.urihttp://hdl.handle.net/11449/233778
dc.language.isoeng
dc.relation.ispartofTranslational Andrology and Urology
dc.sourceScopus
dc.subjectCopy number alterations (CNAs)
dc.subjectMutational profiling
dc.subjectPenile squamous cell carcinoma (PeSCC)
dc.subjectTreatment, biomarkers
dc.titleSystemic treatment of penile squamous cell carcinoma—hurdles and hopes of preclinical models and clinical regimens: a narrative reviewen
dc.typeResenha

Arquivos

Coleções

Artigos - Genética - IBB